论文部分内容阅读
目的:为研究趋化因子配体18(CLL18)在肝癌患者外周血中的表达,探讨其在肝癌癌浸润、转移中的作用。方法:选取2008.1-2010.12年我科的原发性肝癌患者,均经病理或临床确诊,年龄18～70岁,如曾实施化疗,须化疗结束1个月以上而有实体瘤者或手术未能切除者。有转移组50例,其中男性25例,女性25例。无转移组50例,其中男性25例,女性25例。对照组50例,为正常健康人群50例,其中男性25例,女性25例。以ELISA法检测外周血CCL18含量。结果:有转移组患者外周血中CCL18浓度为(137.63±35.56)pg/mL显著高于健康人(47.53±17.22)pg/mL(P<0.05)。无转移组患者外周血中CCL18浓度为(260.27±73.41)pg/mL显著高于健康人(P<0.05)。结论:肝癌患者血浆中的CCL18水平显著高于正常人,并能反映肝癌的进展,有助于对肝癌患者进行预后判断,具有一定的临床价值。
Objective: To investigate the expression of chemokine ligand 18 (CLL18) in peripheral blood of patients with hepatocellular carcinoma (HCC) and to explore its role in the invasion and metastasis of hepatocellular carcinoma. Methods: Selected from 2008.1-2010.12 years of our department of primary liver cancer patients were pathologically or clinically diagnosed, aged 18 to 70 years old, such as the implementation of chemotherapy, to be the end of chemotherapy for more than 1 month and solid tumor or surgery failed Excision. There are 50 cases of metastasis, including 25 males and 25 females. There were 50 cases without metastasis, including 25 males and 25 females. Control group of 50 patients, 50 healthy people, including 25 males and 25 females. The content of CCL18 in peripheral blood was detected by ELISA. Results: The CCL18 concentration in the peripheral blood of patients with metastasis was (137.63 ± 35.56) pg / mL significantly higher than that of healthy people (47.53 ± 17.22) pg / mL (P <0.05). The concentration of CCL18 in the peripheral blood of patients without metastasis was (260.27 ± 73.41) pg / mL, which was significantly higher than that of healthy people (P <0.05). Conclusion: The level of CCL18 in plasma of patients with hepatocellular carcinoma is significantly higher than that of normal people and can reflect the progress of hepatocellular carcinoma, which is helpful to predict the prognosis of patients with hepatocellular carcinoma and has certain clinical value.